Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late April, its bigger-than-expected net loss rattled investors.
The company announced its second-quarter results after the market closed on Wednesday, and the news wasn't any better than earlier this year. Here are the highlights.
Image source: Getty Images.
Source: Fool.com
Illumina Inc. Aktie
107,86 €
-5,59 %
Die Community bevorzugt Illumina Inc., mit deutlich mehr Buy- (27) als Sell-Einschätzungen (4).
Ein Kursziel von 162 € für Illumina Inc. würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 107.86 € bedeuten.
